AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
news12 August 2022 | By Hannah Balfour (European Pharmaceutical Review)
Almost half of patients with EGFR-mutated lung cancer with high MET overexpression who had progressed on Tagrisso alone responded to treatment with the addition of savolitinib.
news8 August 2022 | By Hannah Balfour (European Pharmaceutical Review)
For allegedly underpaying rebates, Eli Lilly has been ordered to pay more than $61 million in damages, an amount that lawyers say will be trebled for the final judgement.
news12 July 2022 | By Caroline Peachey (European Pharmaceutical Review)
AstraZeneca announces plans to acquire TeneoTwo and its CD19/CD3 T-cell engager, TNB-486, in a deal worth up to $1.2bn.
news27 June 2022 | By Hannah Balfour (European Pharmaceutical Review)
The investment in new drug substance production equipment and warehousing facilities to enhance Alexion’s biologics manufacturing in Ireland.
news24 June 2022 | By Sarah Wills (European Pharmaceutical Review)
Data in the NEURO-TTRansform study demonstrates that eplontersen had a positive impact on disease progression, including improvement in neuropathy impairment and quality of life in a substantial number of patients.
news22 June 2022 | By European Pharmaceutical Review
Lynparza (Olaparib) in combination with abiraterone plus prednisone reduced the risk of disease progression or death by 34 percent in the Phase III PROpel trial for prostate cancer patients.
article21 June 2022 | By Hannah Balfour (European Pharmaceutical Review)
With two knighthoods in the last month, here EPR discusses five developments in the drug development community’s C-suite.
news8 June 2022 | By Mandy Parrett (European Pharmaceutical Review)
AstraZeneca's Evusheld (tixagevimab and cilgavimab) provided clinically and statistically significant protection against progression to severe COVID-19 over placebo.
news24 May 2022 | By Hannah Balfour (European Pharmaceutical Review)
New study suggests that Tryptone Soya Agar (TSA) settle plate desiccation during exposure can reduce recovery of airborne microbes.
news23 May 2022 | By Sarah Wills (European Pharmaceutical Review)
A unique partnership, the Access to Oncology Medicines (ATOM) Coalition, has been established to ensure sustainable access to cancer medicines in low- and lower middle-income countries (LLMICs) in the long-term.
news20 May 2022 | By European Pharmaceutical Review
AstraZeneca has entered into a licence agreement with RQ Biotechnology Ltd for a portfolio of early-stage monoclonal antibodies (mAbs) targeted against SARS-CoV-2.
news18 May 2022 | By Mandy Parrett (European Pharmaceutical Review)
The Phase III MANDALA trial has demonstrated that the combination medication PT027 significantly reduces the risk of severe exacerbation in patients with moderate to severe asthma, reports AstraZeneca.
news4 May 2022 | By Mandy Parrett (European Pharmaceutical Review)
AstraZeneca has announced plans to invest in a new facility, uniting its R&D activities with commercial and corporate functions in Boston, US.
news21 April 2022 | By European Pharmaceutical Review
Phase III trial shows Evusheld (tixagevimab and cilgavimab) significantly reduces the risk of developing symptomatic COVID-19 in vulnerable populations.
news8 April 2022 | By Hannah Balfour (European Pharmaceutical Review)
New Ultomiris (ravulizumab-cwvz) follow-up data shows sustained functional improvements in certain adults with generalised myasthenia gravis (gMG).
![Alexion Pharmaceuticals company logo displayed on a smart phone screen [Credit: IgorGolovniov/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Alexion-1-e1656323649599-300x278.jpg)
![Alexion Pharmaceuticals company logo displayed on a smart phone screen [Credit: IgorGolovniov/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Alexion-1-e1656323657672.jpg)
